secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2026-11-10T21:50:52+00:00
Accession:  0001728117-26-000116
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Gossamer Bio files first NDA for seralutinib in PAH; Q3 net loss $48.1M, cash $51.2M
--------------------------------------------------------------------------------

- NDA for seralutinib in PAH submitted to FDA in September 2026, backed by Phase 3 PROSERA plus Phase 2 TORREY; FDA acceptance would unlock ~$125M.
- Q3 2026 revenue from collaborators $38.4M vs $13.3M a year earlier, driven by $25.1M recognized on the July 2026 Chiesi collaboration termination.
- Net loss $48.1M ($7.36/share) vs $48.2M ($16.92/share) in Q3 2025; R&D fell to $18.8M from $45.5M on lower seralutinib trial costs; G&A $9.6M.
- Cash, equivalents and marketable securities $51.2M at Sept 30, 2026, down from $57.0M at June 30; structured placement delivered $25M upfront.
- 1-for-80 reverse stock split completed September 2026 to regain Nasdaq minimum bid price compliance; trading continues as GOSS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000116/0001728117-26-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000116/goss-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001728117-26-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer